Ledger.Open graph →

SEC Form D · filed December 23, 2022

Genesis Therapeutics, Inc

Offering

$23.9M

Sold

$23.9M

Exemption

Rule 506(b)

Industry

Biotechnology

Location

BURLINGAME, CA

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (19)

Leonard Bell · BURLINGAME, CADirector Evan Feinberg · BURLINGAME, CAExec · Director Peptiboon Prasit · BURLINGAME, CADirector Benjamin Sklaroff · BURLINGAME, CAExec Kris Jenner · BURLINGAME, CADirector Rob Schultz · LARAMIE, WYDirector Edward C. Hamburg · LARAMIE, WYExec · Director Shane C. Schulz · LARAMIE, WYDirector Michael Berolzheimer · SAN FRANCISCO, CAExec Bee Partners Iv GP, LLC · SAN FRANCISCO, CADirector Stephen Dann · BURLINGAME, CAExec William Mccarthy · BURLINGAME, CAExec Edward Schulak · Cambridge, MAExec · Director David Sinclair · Cambridge, MADirector Carlos Bustamante · Cambridge, MADirector Space Angels LLC · New York, NYDirector Paul H. Finnen · Jackson, WYExec Stephen Dann · BURLINGAME, CAExec William Mccarthy · BURLINGAME, CAExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗